212 related articles for article (PubMed ID: 8328312)
1. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.
Body JJ; Dumon JC; Thirion M; Cleeren A
J Bone Miner Res; 1993 Jun; 8(6):701-6. PubMed ID: 8328312
[TBL] [Abstract][Full Text] [Related]
2. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer.
Burtis WJ; Brady TG; Orloff JJ; Ersbak JB; Warrell RP; Olson BR; Wu TL; Mitnick ME; Broadus AE; Stewart AF
N Engl J Med; 1990 Apr; 322(16):1106-12. PubMed ID: 2320080
[TBL] [Abstract][Full Text] [Related]
3. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
4. Hypercalcemia of malignancy: a study of clinical features and relationships among circulating levels of calcium, parathyroid hormone and parathyroid hormone-related peptide.
Sriussadaporn S; Phoojaroenchanachai M; Ploybutr S; Plengvidhya N; Peerapatdit T; Nitiyanant W; Vannasaeng S; Vichayanrat A
J Med Assoc Thai; 2007 Apr; 90(4):663-71. PubMed ID: 17487119
[TBL] [Abstract][Full Text] [Related]
5. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy.
Schilling T; Pecherstorfer M; Blind E; Leidig G; Ziegler R; Raue F
J Clin Endocrinol Metab; 1993 Mar; 76(3):801-3. PubMed ID: 8445039
[TBL] [Abstract][Full Text] [Related]
7. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
8. Urinary excretion of parathyroid hormone-related protein as a predictor of hypercalcemia in patients with adult T-cell leukemia.
Imamura H; Koreeda Y; Okadome T; Tara M; Niina K; Shizume K; Ohsumi K; Sato K
Jpn J Clin Oncol; 1992 Oct; 22(5):325-30. PubMed ID: 1469794
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid-hormone-related peptide in hematologic malignancies.
Kremer R; Shustik C; Tabak T; Papavasiliou V; Goltzman D
Am J Med; 1996 Apr; 100(4):406-11. PubMed ID: 8610726
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic significance of parathyroid hormone-related protein in tumor patients with hypercalcemia].
Blind E; Raue F; Meinel T; Pecherstorfer M; Räth U; Schmidt-Gayk H; Kohl B; Ziegler R
Dtsch Med Wochenschr; 1993 Mar; 118(10):330-5. PubMed ID: 8453901
[TBL] [Abstract][Full Text] [Related]
11. Hypercalcemic complication in patients with oral squamous cell carcinoma.
Iwase M; Takemi T; Manabe M; Nagumo M
Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
[TBL] [Abstract][Full Text] [Related]
12. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of parathyroid hormone-related peptide are elevated in hyperprolactinemia and correlated to bone density status.
Stiegler C; Leb G; Kleinert R; Warnkross H; Ramschak-Schwarzer S; Lipp R; Clarici G; Krejs GJ; Dobnig H
J Bone Miner Res; 1995 May; 10(5):751-9. PubMed ID: 7639111
[TBL] [Abstract][Full Text] [Related]
14. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
[TBL] [Abstract][Full Text] [Related]
16. Raised plasma concentrations of parathyroid hormone related peptide in hypercalcemic multiple myeloma.
Horiuchi T; Miyachi T; Arai T; Nakamura T; Mori M; Ito H
Horm Metab Res; 1997 Sep; 29(9):469-71. PubMed ID: 9370119
[TBL] [Abstract][Full Text] [Related]
17. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
Blind E; Raue F; Meinel T; Wüster C; Ziegler R
Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of parathyroid hormone-related peptide in the assessment of hypercalcemia.
Fritchie K; Zedek D; Grenache DG
Clin Chim Acta; 2009 Apr; 402(1-2):146-9. PubMed ID: 19168044
[TBL] [Abstract][Full Text] [Related]
19. Tumor-induced hypercalcemia and parathyroid hormone-related protein in lung carcinoma.
Takai E; Yano T; Iguchi H; Fukuyama Y; Yokoyama H; Asoh H; Ichinose Y
Cancer; 1996 Oct; 78(7):1384-7. PubMed ID: 8839542
[TBL] [Abstract][Full Text] [Related]
20. Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas.
Mitlak BH; Hutchison JS; Kaufman SD; Nussbaum SR
Horm Metab Res; 1991 Jul; 23(7):344-6. PubMed ID: 1663481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]